Tag Archive | "Bristol-Myers Squibb"

Lilly snags rights to Erbitux from BMS

Tags: , , ,


Eli Lilly and Bristol-Myers Squibb announced that the companies have agreed to transfer rights to Erbitux (cetuximab) in North America Read the full story

BMS and UniQure in $1bn gene therapy pact

Tags: , ,


Agreement provides Bristol-Myers Squibb with exclusive access to uniQure’s gene therapy technology platform for multiple targets in cardiovascular diseases Read the full story

Zai licenses Brivanib from BMS

Tags: , ,


Bristol-Myers Squibb and ZAI Lab have signed a definitive agreement Read the full story

BMS and Bavarian Nordic in Prostvac licensing pact

Tags: , ,


Bavarian Nordic and Bristol-Myers Squibb announced an exclusive option to license and commercialize PROSTVAC Read the full story

BMS and Rigel ink cancer immunotherapies pact

Tags: , ,


Rigel Pharmaceuticals and Bristol-Myers Squibb have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies Read the full story

BMS acquires Flexus Biosciences in $1.25 billion deal

Tags: ,


Bristol-Myers Squibb will acquire all of the outstanding capital stock of Flexus Read the full story

Eli Lilly and BMS study Opdivo combined with galunisertib

Tags: , , ,


Bristol-Myers Squibb and Eli Lilly announced a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) in combination with Lilly’s galunisertib Read the full story

BMS and Seattle evaluate Adcetris and Opdivo combination

Tags: , ,


Seattle Genetics and Bristol-Myers Squibb have entered into a clinical trial collaboration agreement to evaluate the investigational combination of Seattle Genetics’ antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) and Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) in two planned Phase 1/2 clinical trials Read the full story

BMS and Calibr in small molecule anti-fibrotic pact

Tags: , ,


Bristol-Myers Squibb and the California Institute for Biomedical Research (Calibr) announced have entered into a worldwide research collaboration to develop novel small molecule anti-fibrotic therapies Read the full story

BMS, Ono, Kyowa in nivolumab-ogamulizumab clinical evaluation

Tags: , , , ,


Ono Pharmaceutical, Bristol-Myers Squibb Company and Kyowa Hakko Kirin have entered into a clinical trial collaboration agreement to conduct a Phase 1 combination study Read the full story